In addition, Docosahexaenoic acid may reduce fractalkine expression and secretion by inhibiting the tumor necrosis factor‐α signaling pathway in ND patients, thereby alleviating kidney inflammation and oxidative stress and delaying disease progression (Zhou et al. 2018). The gene discussed is CX3CL1; the disease is inflammation.